Efficacy of Breast Cancer Nomograms and Factors Related to Non-Sentinel Lymph Node Metastasis in Breast Cancer: A Cross Sectional Study
Sentinel lymph node (SLN) biopsy for breast cancer was accepted and implemented worldwide. Many researchers found that 50-70% of patients with positive SLN biopsy have no further non-sentinel lymph node (NSLN) metastasis. Memorial Sloan Kettering Cancer Center (MSKCC) and Stanford nomograms are the two online calculators to identify patients who have low risk for NSLN metastasis. Aim to validate MSKCC and Stanford nomograms and to investigate which patient characteristics are effective on NSLN metastasis. Between May 2003 and June 2008 patients who underwent SLN biopsy due to breast cancer enrolled to the study. Patient clinicopathologic features and NSLN status were recorded. NSLN metastasis risks were calculated by MSKCC and Stanford nomograms. The relations between the risk scores and NSLN status, NSLN status and patient features were investigated. Results: The AUC values for MSKCC and Stanford nomograms were 0.651 (p=0.004) and 0.631 (p=0.001) respectively. Mean age of the patients were 51.4 (30-85); mean tumor size were 2.70 cm (0.7-8.5). Micrometastasis, macrometastasis and SLN involvement proportions were found statistically significant for NSLN metastasis. Age, tumor size, histology, grade, lymphatic invasion, multifocality and estrogen receptor status were found statistically insignificant. Both MSKCC and Stanford nomograms weakly predicted NSLN metastasis in our patient group. Although the value of the nomograms seems to be diminished after Z011 study, if improved, they can help physicians and patients to decide whether ALND is beneficial in preventing and controlling loco-regional or systemic disease recurrence.
Keywords: Axillary metastasis, breast cancer, breast cancer nomogram, sentinel lymph node, SLN biopsy
Giuliano AE, Jones RC, Brennan M, et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345-50.
Albertini JJ, Lyman GH, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818-22.
Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339:941-6.
Veronesi U, Paganelli G, Galimberti V, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349:1864-7.
Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst. 1999;91:368–73.
Van Zee KJ, Manasseh DM, Bevilacqua JL, et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10:1140-51.
Kohrt HE, Olshen RA, Bermas HR, et al. Bay Area SLN Study. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66.
Gur AS, Unal B, Ozbek U, et al. Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol. 2010;36:30-5.
Piñero A, Canteras M, Moreno A, et al. Multicenter validation of two nomograms to predict non-sentinel node involvement in breast cancer. Clin Transl Oncol. 2013;15:117-23.
Smidt ML, Kuster DM, van der Wilt GJ, Thunnissen FB, Van Zee KJ, Strobbe LJ. Can the Memorial Sloan-Kettering Cancer Center nomogram predict the likelihood of nonsentinel lymph node metastases in breast cancer patients in the Netherlands? Ann Surg Oncol. 2005; 12:1066-72.
Degnim AC, Reynolds C, Pantvaidya G et al. Nonsentinel node metastasis in breast cancer patients: assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190:543-50.
Lambert LA, Ayers GD, Hwang RF et al. Validation of a breast cancer nomogram fro predicting nonsentinel lymph node metastases after a positive sentinel lymph node biopsy. Ann Surg Oncol. 2006;13:310-20.
Cripe MH, Beran LC, Liang WC, et al. The likelihood of additional nodal disease following a positive sentinel lymph node biopsy in breast cancer patients: validation of a nomogram. Am J Surg. 2006;192:484-7.
Dauphine CE, Haukoos JS, Vargas MP, et al. Evaluation of three scoring systems predicting nonsentinel node metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2007;14:1014-9.
Zgajnar J, Perhavec A, Hocevar M et al. Low performance of the MSKCC nomogram in preoperatively ultrasonically negative axillary lymph node in breast cancer patients. J Surg Oncol. 2007;96:547-53.
Alran S, De Rycke Y, Fourchotte V, et al. Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol. 2007;14:2195-201.
Klar M, Jochmann A, Foeldi M, et al. The MSKCC nomogram for prediction the likelihood of non-sentinel node involvement in a German breast cancer population. Breast Cancer Res Treat. 2008;112:523-31.
Ponzone R, Maggiorotto F, Mariani L, et al. Comparison of two models for the prediction of nonsentinel node metastases in breast cancer. Am J Surg. 2007;193:686-92.
Pal A, Provenzano E, Duffy SW,et al. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95:302-9.
Scow JS, Degnim AC, Hoskin TL, et al. Assessment of the performance of the Stanford online calculator for the prediction of nonsentinel lymph node metastasis in sentinel lymph node-positive breast cancer patients. Cancer. 2009;115:4064-70.
Gur AS, Unal B, Johnson R, et al. Predictive probability of four different breast cancer nomograms for nonsentinel axillary lymph node metastasis in positive sentinel node biopsy. J Am Coll Surg. 2009;208:229-35.
Coufal O, Pavlik T, Fabien P, et al. Predicting non-sentinel lymph node status after positive sentinel biopsy in breast cancer: what model performs the best in a Czech population? Pathol Oncol Res. 2009;15:733-40.
Coutant C, Olivier C, Lambaudie E, et al. Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: a prospective multicenter study. J Clin Oncol. 2009;27:2800-8.
Moghaddam Y, Falzon M, Fulford L, et al. Comparison of three mathematical models for predicting the risk of additional axillary nodal metastases after positive sentinel lymph node biopsy in early breast cancer. Br J Surg. 2010;97:1646-52.
Sanjua´n A, Escaramis G, Vidal-Sicart S, et al. Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: evaluation of two scoring systems. Breast J. 2010;16:134-40.
Hidar S, Harrabi I, Benregaya L, et al. Validation of nomograms to predict the risk of non-sentinel lymph node metastases in North African Tunisian breast cancer patients with sentinel node involvement. Breast. 2011;20:26-30.
Lombardi A, Maggi S, Lo Russo M, et al. Non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node: validation of five nomograms and development of a new predictive model. Tumori. 2011;97:749-55.
Tanaka S, Sato N, Fujioka H, Takahashi Y, Kimura K, Iwamoto M. Validation of online calculators to predict the non-sentinel lymph node status in sentinel lymph node-positive breast cancer patients. Surg Today. 2013;43:163-70.
Ozbas S, Ozmen V, Igci A et al. Predicting the likelihood of nonsentinel lymph node metastases in triple negative breast cancer patients with a positive sentinel lymph node: Turkish Federation of Breast Disease Associations protocol MF09-01. Clin Breast Cancer. 2012;12:63-7.
Sosa JA, Diener-West M, Gusev Y, et al. Association between extent of axillary lymph node dissection and survival in patients with stage I breast cancer. Ann Surg Oncol. 1998;5:140-9.
Hayward J, Caleffi M. The significance of local control in the primary treatment of breast cancer. Arch Surg 1987;122:1244-7.
Osteen RT, Harris JR. Patients with early breast cancer benefit from effective axillary treatment. Breast Cancer Res Treat. 1985;5:17-21.
Giuliano AE, McCall L, Beitsch P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252:426-32.
Caudle AS, Hunt KK, Tucker SL, et al. American College of Surgeons Oncology Group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012;19:3144-51.
- Şu halde refbacks yoktur.
This work is licensed under a Creative Commons Attribution 3.0 License.